Skip to main content
. 2020 Aug 8;13(11):100842. doi: 10.1016/j.tranon.2020.100842

Fig. 2.

Fig. 2

Decrease in the proliferative index, cells in S phase and PCNA expression after MET/6-AN treatment. Melanoma cells were treated with metformin (MET, 5 mM), 6-aminonicotinamide (6-AN, 50 μM) or a combination of both (MET/6-AN). After 48 h of treatment, nuclei were stained with DAPI and immuno-stained with (A) a monoclonal antiKi67 antibody to evaluate the proliferation index or (B) a monoclonal antiBrdU antibody to determine the number of cells in S phase. Images were obtained at 400 magnification. Results are expressed as means ± SEM of three independent experiments. Statistical analysis (A and B) was performed with one-way ANOVA using Tukey's multiple comparisons test to calculate significance (*p < .05, **p < .01 and ***p < .001 respect to control treated with PBS, ○○○p < .001 respect to MET 5 mM and ●●●p < .001 respect to 6-AN 50 μM). (C) Representative immunoblot analysis showing the level of PCNA after 48 h treatment of two independent experiments.